Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

Table 5 Healthcare resource utilisation during follow-up

	PF-ILD (n = 14,413)
	Patients with ≥ 1, n (%)	Median annual, n (IQR)^a
Medical visits
General practitioners visits	12,476 (86.6)	11.2 (6.9–17.4)
Pulmonary specialist visits	8870 (61.5)	2.1 (1.1–3.9)
Nursing acts	11,301 (78.4)	17.6 (5.1–65.6)
Physiotherapy acts	7982 (55.4)	17.5 (6.1–50.5)
Hospitalisations
All-cause hospitalisation	13,727 (95.2)	3.9 (1.7–9.5)
Acute event hospitalisation	10,835 (75.2)	1.8 (0.7–4.8)
Pulmonary hypertension hospitalisation	1591 (11.0)	0.9 (0.4–2.1)
ICU	4944 (34.3)	0.8 (0.4–2.4)
Ambulance use	12,176 (84.5)	7.8 (3.1–16.1)
Sick leave daily allowances	1630 (11.3)	9.2 (3.7–19.5)
Laboratory analyses	11,293 (78.4)	12.2 (5.9–24.5)
Pulmonary function tests	10,670 (74.0)	3.1 (1.6–5.7)
Imaging
Pulmonary imaging	12,858 (89.2)	3.9 (2.1–7.8)
Chest X-ray	12,258 (85.0)	2.6 (1.3–5.6)
Chest or body scan	9971 (69.2)	1.4 (0.7–2.6)

End of follow-up was defined as the earliest of patient death, end of study period (31 December 2017) or last available record (hospitalisation, consultation or healthcare reimbursement) in the data source. Patients with a data gap persisting beyond 12 months are considered to have their follow-up ceased at their last record
ICU intensive care unit, IQR interquartile range, PF-ILD progressive fibrosing interstitial lung disease
^aMedian annual value for those with ≥ 1 claim during the study period

ISSN: 1465-993X